A handful of small, early-stage clinical trials are investigating whether CAR-T therapy can improve symptoms in multiple ...

That superhero is a gene called TP53, and for decades scientists have known it as the “guardian of the genome.” In a healthy cell, TP53 acts like both a brake and an emergency stop button. When DNA ...

CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients navigating a chronic ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

HealthDay News — In guidelines issued by the American Society of Hematology and published online Feb. 11 in Blood Advances, recommendations are presented for frontline management of acute ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...